Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician

PURPOSE OF REVIEW: Biosimilars of the reference biologic therapeutics infliximab, etanercept, adalimumab, and rituximab are entering the market. Clinical and real-world data on the effects of reference → biosimilar switching are limited. This review was carried out to assess the current body of swit...

Descripción completa

Detalles Bibliográficos
Autores principales: Moots, Robert, Azevedo, Valderilio, Coindreau, Javier L., Dörner, Thomas, Mahgoub, Ehab, Mysler, Eduardo, Scheinberg, Morton, Marshall, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Biosimilars (E Mysler, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486595/
https://www.ncbi.nlm.nih.gov/pubmed/28623625
http://dx.doi.org/10.1007/s11926-017-0658-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486595/
https://www.ncbi.nlm.nih.gov/pubmed/28623625
http://dx.doi.org/10.1007/s11926-017-0658-4

Ejemplares similares